Featured Content |Content Library
Dana-Farber Cancer Institute is encouraging a public dialogue to raise awareness about colorectal cancer disparities by race and ethnicity, and the importance of screening for colorectal cancer, the third most common cancer among men and ...
Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven't received such therapies in the three months before their COVID diagnosis, show findings ...
The biology of rare cancers is poorly understood in part because the tumors are uncommon, which makes them challenging to study. Clinical trials examining rare cancers are difficult.
Kornelia Polyak, M.D., Ph.D., professor of medicine, medical oncology, Dana-Farber Cancer Institute has been elected to the prestigious National Academy of Medicine.
The Dana-Farber community mourns the passing of Arthur T. Skarin, MD, of Needham, Massachusetts.
Receive Dana-Farber's e-newsletter, Momentum, to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.
- Center for Protein Degradation - Royal Chemistry Society
- Breast Cancer Treatment
- Research News Updates
- Faculty Updates
- Symposium Highlights 75 Years of Dana-Farber Science
- American Society of Hematology (ASH) Annual Meeting